Want to see SE:ACE full AI Analyst Report?
Top Page
Ascelia Pharma AB
(ACE)
Select Model
Select Model
Rating:47Neutral
Price Target:
kr0.78
▼(-75.39% Downside)
Action:Reiterated
Date:10/01/26
The score is held back primarily by weak financial performance (pre-revenue, sizable ongoing losses and negative free cash flow) despite improving burn trends and very low leverage. Technicals are mixed—short-term stabilization but a longer-term downtrend. Valuation provides limited support because losses drive a negative P/E and no dividend yield is available.
Positive Factors
Very Low Leverage
Minimal leverage reduces solvency and refinancing pressure while preserving financial flexibility for continued clinical development. A largely unlevered balance sheet can also make it easier to pursue partnerships or raise capital without adding substantial interest obligations before commercialization.
Negative Factors
Pre-Revenue Business Model
The absence of operating revenue means the company has not yet demonstrated product-market adoption, pricing power, or commercial execution. Near-term business value remains tied to regulatory and launch milestones, leaving limited diversification if the lead product is delayed or unsuccessful.
Read all positive and negative factors
Positive Factors
Negative Factors
Very Low Leverage
Minimal leverage reduces solvency and refinancing pressure while preserving financial flexibility for continued clinical development. A largely unlevered balance sheet can also make it easier to pursue partnerships or raise capital without adding substantial interest obligations before commercialization.
Read all positive factors
Ascelia Pharma AB (ACE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr84.26M
Dividend YieldN/A
Average Volume (3M)767.81K
Price to Earnings (P/E)―
Beta (1Y)0.68
Revenue GrowthN/A
EPS Growth58.15%
CountrySE
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.48
Shares Outstanding133,535,460
10 Day Avg. Volume401,544
30 Day Avg. Volume767,812
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-5.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.27
Revenue Forecast (FY)kr6.10M
Ascelia Pharma AB Business Overview & Revenue Model
Company Description
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical tr...
How the Company Makes Money
Ascelia Pharma’s business model is centered on successfully developing, obtaining regulatory approval for, and then commercializing its product candidates, with future revenues expected to come primarily from product sales of its lead candidate, O...
Ascelia Pharma AB Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
58
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -888.00K | -938.00K | -1.05M | -3.89M | -8.72M |
| EBITDA | -59.92M | -73.24M | -67.69M | -108.56M | -132.06M | -128.42M |
| Net Income | -60.13M | -76.25M | -80.03M | -109.29M | -131.22M | -125.90M |
Balance Sheet | ||||||
| Total Assets | 100.23M | 111.94M | 140.92M | 87.07M | 218.57M | 333.49M |
| Cash, Cash Equivalents and Short-Term Investments | 38.05M | 49.86M | 75.26M | 21.86M | 149.56M | 261.60M |
| Total Debt | 490.00K | 1.04M | 25.40M | 1.06M | 484.00K | 1.66M |
| Total Liabilities | 10.40M | 12.47M | 61.98M | 12.74M | 37.71M | 25.66M |
| Stockholders Equity | 89.83M | 99.47M | 78.94M | 74.33M | 180.86M | 307.83M |
Cash Flow | ||||||
| Free Cash Flow | -67.19M | -72.31M | -62.84M | -126.79M | -125.33M | -116.60M |
| Operating Cash Flow | -67.19M | -72.25M | -62.84M | -126.79M | -125.26M | -116.56M |
| Investing Cash Flow | 0.00 | -57.00K | 0.00 | 46.00K | -65.00K | -38.00K |
| Financing Cash Flow | 45.00M | 48.21M | 115.19M | -936.00K | -1.10K | 184.87M |
Ascelia Pharma AB Technical Analysis
Positive
3.17
Price Trends
0.60
Positive
1.46
Negative
2.23
Negative
Market Momentum
<0.01
Negative
69.81
Neutral
64.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACE, the sentiment is Positive. The current price of 3.17 is above the 20-day moving average (MA) of 0.64, above the 50-day MA of 0.60, and above the 200-day MA of 2.23, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 69.81 is Neutral, neither overbought nor oversold. The STOCH value of 64.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ACE.
Ascelia Pharma AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | kr396.98M | 2.24 | 63.09% | ― | ― | ― | |
53 Neutral | kr859.58M | -2.80 | ― | ― | 87.23% | 35.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr399.63M | -3.54 | -18.05% | ― | ― | 15.97% | |
47 Neutral | kr84.26M | -1.64 | -62.21% | ― | ― | 58.15% | |
43 Neutral | kr1.48B | -3.04 | -99.58% | ― | -87.22% | -70.29% | |
42 Neutral | kr80.41M | -1.80 | -2775.09% | ― | 115.26% | -230.43% |
* Healthcare Sector Average
SE:ACE
Ascelia Pharma AB
0.79
-2.61
-76.74%
SE:BINV
BioInvent International AB
22.95
-5.20
-18.47%
SE:ONCO
Oncopeptides AB
2.19
-2.79
-56.03%
SE:ONCOZ
OncoZenge AB
3.45
-1.24
-26.42%
SE:IMMU
Immunicum AB
6.34
-0.56
-8.12%
SE:CANTA
Cantargia AB
1.52
-1.28
-45.57%
Ascelia Pharma AB Corporate Events
Ascelia Pharma’s Orviglance Study Published in Leading MRI Journal
Sep 24, 2026
Ascelia Pharma AB, a Malmö-based biotech company listed on Nasdaq Stockholm and focused on orphan oncology treatments, is developing two key drug candidates: Orviglance, a manganese-based MRI contrast agent for liver imaging, and Oncoral. The...
Ascelia Pharma Holds FDA Type A Meeting on Orviglance NDA
Sep 10, 2026
Ascelia Pharma has completed a Type A meeting with the U.S. Food and Drug Administration to discuss the Complete Response Letter issued for the Orviglance New Drug Application. The meeting was aimed at clarifying the steps required to secure U.S. ...
Ascelia Pharma Tightens Costs After FDA Setback on Orviglance
Aug 20, 2026
Ascelia Pharma reported that its primary focus in the first half of 2026 has been advancing Orviglance through the U.S. regulatory process and preparing for potential commercial partnering once approval is secured. The company completed a SEK 20 m...
Ascelia Pharma Secures FDA Type A Meeting on Orviglance NDA
Aug 17, 2026
Ascelia Pharma said the U.S. Food and Drug Administration has scheduled a Type A meeting on September 9, 2026 to discuss the Complete Response Letter issued for the New Drug Application of Orviglance. The meeting will allow the company and the reg...
Ascelia Pharma Restructures and Cuts Costs to Sharpen Focus on Orviglance
Jul 15, 2026
Ascelia Pharma has announced organizational changes and cost reduction measures, including the planned departure of Chief Financial Officer Anton Hansson in late August 2026 and a restructuring that will see the finance function report directly to...
Ascelia Pharma Defends Orviglance Data After FDA Complete Response Letter
Jul 12, 2026
Ascelia Pharma has provided an update on its MRI contrast agent candidate Orviglance after the U.S. Food and Drug Administration issued a Complete Response Letter on its New Drug Application. The company maintains that its pivotal phase 3 SPARKLE ...
Ascelia Pharma Receives FDA Complete Response Letter on Orviglance NDA
Jul 3, 2026
Ascelia Pharma AB, a Malmö-based biotech company focused on orphan oncology treatments for rare cancer-related conditions, is advancing a pipeline led by its drug candidates Orviglance and Oncoral. Listed on Nasdaq Stockholm under ticker ACE,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.